NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients

Abstract: We evaluated the genetic impact of the amyotrophic lateral sclerosis (ALS) risk gene never in mitosis gene arelated kinase 1 (NEK1) in a Belgian cohort of 278 patients with ALS (n = 245) or ALS with frontotemporal dementia (ALS-FTD, n = 33) and 609 control individuals. We identified 2 ALS patients carrying a loss-of-function (LOF) mutation, p.Leu854Tyrfs*2 and p.Tyr871Valfs*17, that was absent in the control group. A third LOF variant p.Ser1036* was present in 2 sibs with familial ALS but also in an unrelated control person. Missense variants were common in both patients (3.6%) and c... Mehr ...

Verfasser: Nguyen Phuoc, Hung
Van Mossevelde, Sara
Dillen, Lobke
De Bleecker, Jan L.
Moisse, Matthieu
Van Damme, Philip
Van Broeckhoven, Christine
van der Zee, Julie
Engelborghs, Sebastiaan
Crois, Roeland
De Deyn, Peter Paul
De Jonghe, Peter
Baets, Jonathan
Cras, Patrick
Mercelis, Rudolf
Vandenberghe, Rik
Sieben, Anne
Santens, Patrick
Ivanoiu, Adrian
Deryck, Olivier
Vanopdenbosch, Olivier
Delbeck, Jean
Dokumenttyp: Artikel
Erscheinungsdatum: 2018
Schlagwörter: Biology / Human medicine
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26915969
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://hdl.handle.net/10067/1470010151162165141

Abstract: We evaluated the genetic impact of the amyotrophic lateral sclerosis (ALS) risk gene never in mitosis gene arelated kinase 1 (NEK1) in a Belgian cohort of 278 patients with ALS (n = 245) or ALS with frontotemporal dementia (ALS-FTD, n = 33) and 609 control individuals. We identified 2 ALS patients carrying a loss-of-function (LOF) mutation, p.Leu854Tyrfs*2 and p.Tyr871Valfs*17, that was absent in the control group. A third LOF variant p.Ser1036* was present in 2 sibs with familial ALS but also in an unrelated control person. Missense variants were common in both patients (3.6%) and controls (3.0%). The missense variant, p.Arg261His, which was previously associated with ALS risk, was detected with a minor allele frequency of 0.90% in patients compared to 0.33% in controls. Taken together, NEK1 LOF variants accounted for 1.1% of patients, although interpretation of pathogenicity and penetrance is complicated by the observation of occasional LOF variants in unaffected individuals (0.16%). Furthermore, enrichment of additional ALS gene mutations was observed in NEK1 carriers, suggestive of a second hit model were NEK1 variants may modify disease presentation of driving mutations.